JPRN-UMIN000031044已完成未知
Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Degludec in Patients with Type 2 Diabetes: A Randomized, Open-Label, Crossover Study Using Continuous Glucose Monitoring Profiles - Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Degludec in Patients with Type 2 Diabetes: A Randomized, Open-Label, Crossover Study Using Continuous Glucose Monitoring Profiles
Minamiosaka Hospital0 个研究点目标入组 30 人开始时间: 2018年1月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Serious ketosis, history of diabetic coma or precoma 2.Pregnancy or lactation and patients scheduled 3.Serious infection, trauma, undergo surgery 4.Receiving steroid therapy. 5.Severe liver dysfunction 6.Type 1 diabetes 7.Hypersensitivity to degludec/aspart, glargin, glulisine. 8.History of malignancy or malignancy. 9.Judged to be unsuitable for participation for medical reasons.
研究者
相似试验
已完成
不适用
Efficacy and safety of insulin glargine 300 U/ml versus 100 U/ml in type 2 diabetic patients treated with basal insulin plus GLP-1 receptor agonisttype 2 diabetesJPRN-UMIN000019353Shiraiwa Medical Clinic30
已完成
不适用
Efficacy and safety of insulin glargine 300 U/ml versus 100 U/ml in type 2 diabetic patients treated with basal insulin plus oral hypoglycemic agentstype 2 diabetesJPRN-UMIN000019354Shiraiwa Medical Clinic60
尚未招募
不适用
A clinical trial to study the effect of insulin glargine injection given earlier during diabetic ketoacidosis (DKA) along with regular treatment as compared to regular treatment alone in children with Type-1 DiabetesCTRI/2022/11/047612Aster Intramural funding
招募中
不适用
Comparison of efficacy and safety of insulin glargine U-100/lixisenatide and insulin degludec/liraglutide in type 2 diabetes patientstype 2 Diabetes mellitusJPRN-UMIN000047518Minami Osaka Hospital36
招募中
不适用
Efficacy and safety of once daily insulin glargine therapy for people with type 2 diabetes inadequately controlled with DPP4 inhibitor and several OADsType 2 DiabetesJPRN-UMIN000007375Tokyo Medical University100